


L5 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2005:161048 CAPLUS Full-text  
 DN 142:235497  
 TI Peptide deformylase inhibition and antimicrobial activity of  
 heteroarylenes  
 IN Aubart, Kelly M.; Benowitz, Andrew B.; Christensen, Siegfried Benjamin,  
 IV; Lee, Jinhwa; Silva, Domingos J.  
 PA Smithkline Beecham Corporation, USA  
 SO PCT Int. Appl., 42 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005017124	A2	20050224	WO 2004-US26574	20040812
	WO 2005017124	A3	20051215		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,				
	CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,				
	GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,				
	LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,				
	NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,				
	TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW:				
	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,				
	AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,				
	EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,				
	SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,				
	SN, TD, TG				
	EP 1654239	A2	20060510	EP 2004-781288	20040812
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
	IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
	JP 2007502825	T	20070215	JP 2006-523966	20040812
PRAI	US 2003-495521P	P	20030815		
	WO 2004-US26574	W	20040812		
OS	MARPAT 142:235497				
GI					



AB Novel peptide deformylase inhibitors and novel methods for their use as  
 antibacterial compds. are provided. Thus, a detailed synthetic scheme for N-  
 {[(5R)-16-(dimethylamino)-4-oxo-2,3,16,17,18- pentaazabicyclo[12.3.1]octadeca-  
 1(18),14,16-trien-5-yl)methyl]-N- hydroxyformamide (I) is demonstrated.  
 Inhibition of Staphylococcus aureus or Escherichia coli peptide deformylase  
 activity is demonstrated using a continuous formate dehydrogenase-coupled  
 spectrophotometric assay developed by Lazennec & Meinnel (1997), and whole-  
 cell antimicrobial activity is determined by broth microdilution using the  
 National Committee for Clin. Laboratory Stds. recommended procedure with a  
 panel of 12 strains.

IT 845533-89-3P 845533-90-6P 845533-91-7P  
 845533-92-8P 845533-93-9P 845533-94-0P  
 845533-95-1P 845533-96-2P 845533-97-3P  
 845533-98-4P 845533-99-5P 845534-00-1P  
 845534-01-2P 845534-02-3P 845534-03-4P

845534-04-5P


RL: BSU (Biological study, unclassified); PAC (Pharmacological activity);  
SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological  
study); PREP (Preparation); USES (Uses)

(peptide deformylase inhibition and antimicrobial activity of  
heteroarylenes)

RN 845533-89-3 CAPLUS

CN Formamide, N-[[ (5R)-16-(dimethylamino)-4-oxo-2,3,15,17,18-  
pentaazabicyclo[12.3.1]octadeca-1,14,16-trien-5-yl]methyl]-N-hydroxy-  
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 845533-90-6 CAPLUS

CN Formamide, N-hydroxy-N-[[ (5R)-16-(4-morpholinyl)-4-oxo-2,3,15,17,18-  
pentaazabicyclo[12.3.1]octadeca-1,14,16-trien-5-yl]methyl]- (9CI) (CA  
INDEX NAME)


Absolute stereochemistry.



RN 845533-91-7 CAPLUS

CN Formamide, N-[[ (5R)-16-(cyclopropylamino)-4-oxo-2,3,15,17,18-  
pentaazabicyclo[12.3.1]octadeca-1,14,16-trien-5-yl]methyl]-N-hydroxy-  
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 845533-92-8 CAPLUS

CN Formamide, N-hydroxy-N-[[ (5R)-16-(4-morpholinyl)-4-oxo-2,3,17,18-tetraazabicyclo[12.3.1]octadeca-1,14,16-trien-5-yl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 845533-93-9 CAPLUS

CN Formamide, N-hydroxy-N-[[ (5R)-16-methyl-4-oxo-2,3,17,18-tetraazabicyclo[12.3.1]octadeca-1,14,16-trien-5-yl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 845533-94-0 CAPLUS

CN Formamide, N-hydroxy-N-[[ (5R)-4-oxo-2,3,16,17-tetraazabicyclo[11.3.1]heptadeca-1,13,15-trien-5-yl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 845533-95-1 CAPLUS

CN Formamide, N-hydroxy-N-[[ (5R)-15-methyl-4-oxo-2,3,16,17-tetraazabicyclo[11.3.1]heptadeca-1,13,15-trien-5-yl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 845533-96-2 CAPLUS

CN Formamide, N-hydroxy-N-[[ (5R)-15-(4-morpholinyl)-4-oxo-2,3,16,17-tetraazabicyclo[11.3.1]heptadeca-1,13,15-trien-5-yl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 845533-97-3 CAPLUS

CN Formamide, N-[[ (5R)-15-(2-furanyl)-4-oxo-2,3,16,17-tetraazabicyclo[11.3.1]heptadeca-1,13,15-trien-5-yl]methyl]-N-hydroxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 845533-98-4 CAPLUS

CN Formamide, N-hydroxy-N-[[ (5R)-15-(4-morpholinyl)-4-oxo-2,3,14,16,17-pentaazabicyclo[11.3.1]heptadeca-1,13,15-trien-5-yl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 845533-99-5 CAPLUS

CN Formamide, N-[[ (5R)-15-(dimethylamino)-4-oxo-2,3,14,16,17-pentaazabicyclo[11.3.1]heptadeca-1,13,15-trien-5-yl]methyl]-N-hydroxy-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 845534-00-1 CAPLUS

CN Formamide, N-hydroxy-N-[[ (5R)-4-oxo-2,3,15,16-tetraazabicyclo[10.3.1]hexadeca-1,12,14-trien-5-yl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 845534-01-2 CAPLUS

CN Formamide, N-hydroxy-N-[[ (5R)-14-methyl-4-oxo-2,3,15,16-tetraazabicyclo[10.3.1]hexadeca-1,12,14-trien-5-yl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 845534-02-3 CAPLUS

CN Formamide, N-[[ (5R)-14-(dimethylamino)-4-oxo-2,3,15,16-tetraazabicyclo[10.3.1]hexadeca-1,12,14-trien-5-yl]methyl]-N-hydroxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 845534-03-4 CAPLUS

CN Formamide, N-hydroxy-N-[[ (5R)-14-(4-morpholinyl)-4-oxo-2,3,15,16-tetraazabicyclo[10.3.1]hexadeca-1,12,14-trien-5-yl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 845534-04-5 CAPLUS

CN Formamide, N-[[ (4R)-3,15-dioxo-1,2-diazacyclopentadec-4-yl]methyl]-N-hydroxy- (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN

AN 1975:497341 CAPLUS Full-text

DN 83:97341

OREF 83:15301a,15304a

TI N,N-Di-[4-hydroxy-3,6-dioxohexahydropyridazinyl-(4)-acetyl]-amides

IN Knoevenagel, Kurt; Himmelreich, Rolf

PA C. F. Spiess und Sohn, Fed. Rep. Ger.

SO Ger. Offen., 47 pp.

CODEN: GWXXBX

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	DE 2356368	A1	19750515	DE 1973-2356368	19731112
PRAI	DE 1973-2356368	A	19731112		


AB R2NR1 [I; R = (4-hydroxy-3,6-dioxohexahydro-4-pyridazinyl)acetyl; R1 = H, pentyl, Bu, PrMeCH, hexyl, cyclohexyl, heptyl, dodecyl, Ph, o-HO2CC6H4, PhCH2, 2-oxocyclohexylidenemethyl, OH, CN, Ac, CO2Et, CH2COCO2Et] were obtained by treatment of ROH with R1NH2. Using amino acids in place of amines gave 7 I where R1 was a radical derived from an amino acid. Also obtained were R2N(CH2)nNR2 (n = 2,6), R2NXNR2 [x = bond, CO, CS, CONHCO, C:NR, C(:NH)NHC(:NH)] and 11 addnl. amides. The compds. were useful as plant growth regulators.

IT 56546-61-3P


RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)

RN 56546-61-3 CAPLUS

CN 4-Pyridazineacetamide, N-[(hexahydro-4-hydroxy-3,6-dioxo-4-pyridazinyl)acetyl]hexahydro-N,4-dihydroxy-3,6-dioxo- (9CI) (CA INDEX NAME)



```
=> d l2; d his; log y
L2 HAS NO ANSWERS
L1          STR
```



Structure attributes must be viewed using STN Express query preparation.  
L2 QUE ABB=ON PLU=ON L1

(FILE 'HOME' ENTERED AT 19:53:19 ON 22 APR 2008)

FILE 'REGISTRY' ENTERED AT 19:53:44 ON 22 APR 2008

FILE 'CAPLUS' ENTERED AT 19:53:45 ON 22 APR 2008

FILE 'REGISTRY' ENTERED AT 19:54:01 ON 22 APR 2008

```
L1          STRUCTURE UPLOADED
L2          QUE L1
L3          0 S L2
L4          17 S L2 FUL
```

FILE 'CAPLUS' ENTERED AT 19:54:44 ON 22 APR 2008

```
L5          2 S L4
```

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	11.86	191.37
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-1.60	-1.60

STN INTERNATIONAL LOGOFF AT 19:55:40 ON 22 APR 2008